Stock MY00 KETAMINEONE CAPITAL
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News KetamineOne Capital Deutsche Boerse AG

Equities

MY00

CA4925531028

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Wellbeing Digital Subsidiary KGK Science to Participate at the Mushroom Summit and Psychedelic Science Conference
BU
Wellbeing Digital Enters into Share Purchase Agreement with Cardinal Group
BU
Cardinal Group Companies LLC entered into an agreement to acquire KGK Science Inc. from Wellbeing Digital Sciences Inc. for $2 million.
CI
Wellbeing Digital Subsidiary KGK Science to Participate at the Nutrition Industry Association Spring Conference
BU
Wellbeing Subsidiary KGK Science Announces Successful Results of UP360, a Nutraceutical Ingredient Demonstrating Beneficial Immune Defense Response
BU
Wellbeing Digital Sciences Inc.'s Wholly Owned Subsidiary KGK Sciences Inc Begins Recruitment in First-Of-Its-Kind Health Canada Approved Psilocybin Trial
CI
Wellbeing Subsidiary KGK Science Begins Recruitment in First-of-its-Kind Health Canada Approved Psilocybin Trial
BU
Wellbeing Subsidiary KGK Science Receives Institutional Review Board Approval
BU
Wellbeing Announces Cease Trade Order
BU
IIROC Trading Halt - MEDI
AQ
Wellbeing Provides Bi-Weekly Default Status Report
BU
Wellbeing Digital to Participate at the Benzinga Psychedelic Capital Conference
BU
Wellbeing Digital to Participate at the Cantor Fitzgerald Virtual Panel Discussion
BU
Wellbeing Digital to Participate in The Global Biomedical Design Conference
BU
Wellbeing Subsidiary KGK Science Applies for a Controlled Substances Dealers License and Receives Approval to Proceed with Buildout
BU
Wellbeing Provides Bi-Weekly Default Status Report
BU
Wellbeing Digital to Participate in MarigoldLIVE: International Women’s Day Networking Event
BU
Wellbeing Provides Bi-Weekly Default Status Report
BU
Wellbeing Subsidiary KGK Science Announces Publication of Safety Studies on Paraxanthine and Comparison to Caffeine Toxicity.
BU
Wellbeing Subsidiary KGK Science Receives Exemption Under Section 56 of the Controlled Drugs and Substances Act to Begin Psilocybin Clinical Trial
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MEDI Stock
  4. MY00 Stock
  5. News KetamineOne Capital